SpeeDx Establishes New European Subsidiary

09/06/2016

 

SpeeDx

SpeeDx has announced the establishment of a European subsidiary company to be headquartered in the London Bioscience Innovation Centre. The UK-based headquarters will support the future launch of SpeeDx PlexPCR™ multiplex qPCR assays. SpeeDx has filed for CE-IVD Mark for PlexPCR™ HSV-1&2, VZV for the detection of three different types of herpes viruses and is finalising test submission for Mycoplasma genitalium, a newly-recognised sexually transmitted infection.

“We believe this new European presence is an essential step in supporting the launch of our clinical diagnostic products,” said Colin Denver, Vice President of Sales & Marketing for SpeeDx. “Our range of PlexPCR™ tests will help streamline infectious disease management for laboratories, while our future ResistancePlus™ portfolio can offer labs valuable information about antimicrobial resistance to ultimately influence treatment options.”

Founded in 2009, SpeeDx specialise in innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. SpeeDx has a portfolio of market leading detection and priming technologies to enable new healthcare paradigms based on improved delivery and reduced costs. SpeeDx has a proven track record of scientific discovery and strives to provide cutting edge clinically relevant tools for the clinical diagnostic market.

SpeeDx is a client of ATP Innovations, Australia’s leading advanced technology business incubator.
Twitter Auto Publish Powered By : XYZScripts.com